Modern Radiotherapy Gains Ground in Prostate Cancer Treatment
News related to:Micropos Medical · 3 min read
GOTHENBURG, Sweden, Nov. 4, 2026 /CourierPR/ -- Micropos Medical is driving a shift in awareness and utilization of high-precision radiotherapy for prostate cancer, according to a press release from the company. Modern radiotherapy, they argue, is as effective as surgery but offers significant advantages in preserving urinary continence and sexual function.
Despite growing scientific evidence, radiotherapy remains underutilized in several European countries. According to European guidelines from the European Association of Urology (EAU), nearly all men with non-metastatic prostate cancer who require active treatment are candidates for primary radiotherapy. However, radiotherapy is applied in as few as 12-22% of radically treated patients in some national registries.
This issue was highlighted at Europe's largest scientific congress, ESTRO 2026 (European Society for Radiotherapy and Oncology), in Stockholm, and at the corresponding congress in the United States, ASTRO 2026 (American Society for Radiation Oncology) in Boston. The need to raise awareness of radiotherapy as a modern, effective, and less invasive treatment option received considerable attention.
Professor Filippo Alongi, Director of the Advanced Radiation Oncology department at IRCCS Sacro Cuore Don Calabria Hospital in Italy, highlighted the findings of the Pace-A study, which compared robotic surgery with high-precision radiotherapy delivered in just five sessions. The study, he said, provides significant long-term evidence on patient treatment outcomes, showing that radiotherapy offers advantages over surgery in preserving urinary continence and sexual function.
The press release also notes that the British ProtecT trial had already provided reassuring long-term oncological effectiveness of radiotherapy compared with surgery. More recently, the eight-year follow-up of the PACE-A study reinforces these findings, showing that modern high-precision radiotherapy delivered in just five sessions can offer additional advantages even when compared with the most advanced robotic surgical techniques.
Minimizing side effects, increasing efficiency through fewer treatment sessions, and providing patients with clearer information about radiotherapy were among the key themes discussed at the congress. Professor Piet Ost from GZA Ziekenhuizen in Antwerp, Belgium, emphasized the need to communicate treatment options in a clear and decisive manner, avoiding overly technical details that can confuse patients.
Highly precise stereotactic body radiotherapy (SBRT), enabled by advanced image guidance and real-time motion management, has transformed the treatment of localized prostate cancer. Many patients can now receive a curative, non-invasive treatment in just a few outpatient sessions, achieving cancer control comparable to surgery while better preserving urinary continence, sexual function, and quality of life.
Dr Carmen Rubio Rodriguez, Head of the Radiation Oncology Service of HM Hospitales in Madrid, Spain, and President-Elect of ESTRO, stated that clear, patient-centered terminology helps reduce unnecessary anxiety and gives patients a better understanding of what to expect. She highlighted the importance of ensuring that every eligible patient is informed about this highly effective treatment option.
At the recent ESTRO 2026 Congress in Stockholm, ESTRO President Professor Barbara Jereczek-Fossa emphasized the need to improve communication about radiotherapy.
Dr Berardino de Bari from the Réseau Hospitalier Neuchâtelois in La Chaux-de-Fonds, Switzerland, discussed the importance of technological innovation in prostate radiotherapy.
As treatment is condensed into fewer fractions, accuracy and precision become increasingly important. Modern radiotherapy addresses this challenge through technologies that continuously monitor prostate motion and minimize the risk of radiation to the bladder, other surrounding organs, and healthy tissue.
Hanna Syrén, COO and QA/RA Director at Micropos Medical, concluded that working together across specialties, scientific societies, patient organizations, and industry is essential to ensure that patients receive balanced information, benefit from appropriate technological innovation, and have equitable access to the treatment best suited to their individual needs.